FilingSEC EDGAR8-K
Medicus Pharma Announces Proposed SPAC Merger for Subsidiary SkinJect
· SEC accepted
StageLOI signed
Filing content
The company announced a non-binding letter of intent for a proposed business combination of its subsidiary SkinJect with a SPAC, valuing SkinJect at $135 million.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…